Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Clear Cell Renal Cell Carcinoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Kidney Medullary Carcinoma (96
)
Kidney Medullary Carcinoma (96
)
›
Associations
(93)
News
Trials
Search handles
@AndreaNecchi
@AzadOncology
@DrChoueiri
@DrJJZhang
@DrRanaMcKay
@DrYukselUrun
@EvanHallMD
@LauraBukavinaMD
@MosheOrnsteinMD
@NazliDizman
@ReneeSaliby
@ShaalanBeg
@TiansterZhang
@UrologieParis
@_ShankarSiva
@arihakimi
@cdanicas
@dr_yakupergun
@jgong15
@montypal
@nataliagandur
@neerajaiims
@tompowles1
Search handles
@AndreaNecchi
@AzadOncology
@DrChoueiri
@DrJJZhang
@DrRanaMcKay
@DrYukselUrun
@EvanHallMD
@LauraBukavinaMD
@MosheOrnsteinMD
@NazliDizman
@ReneeSaliby
@ShaalanBeg
@TiansterZhang
@UrologieParis
@_ShankarSiva
@arihakimi
@cdanicas
@dr_yakupergun
@jgong15
@montypal
@nataliagandur
@neerajaiims
@tompowles1
Filter by
Latest
9ms
14/16 #TumorBoardTuesday #KidneyCancer #RCC 📌VHL Syndrome 🧬Genetically inherited RCC with VHL mut 💊PO belzutifan blocks HIF: 49% ORR with time to tx response ➡️ 8 mos 🔹Loss of VHL function drives 90% of sporadic ccRCC via upregulation of HIF @VHLAlliance (@katy_beckermann)
9 months ago
Welireg (belzutifan)
10ms
Two presentations in a row on single cell analysis of nccRCC subtypes with @Chrislabaki1 now presenting his great work on chromophobe RCC @BraunMDPhD @DrChoueiri #henskelab #KCRS23 (@srviswanathan)
10 months ago
10ms
S6: Immunotherapy Advances and Research 🧬 Derepression of Human Endogenous Retrovirus and Implications for IO for ccRCC HIF is a transcription factor for hERV ❓How does HIF inhibition interact with ICI ❓ #QinqinJiang @kaelin_lab @BraunMDPhd @DanaFarber @kidneycan #KCRS23 (@MikeSerzanMD)
10 months ago
10ms
Also terrific talk by @ChungHanLee3 on nccRCC. Exciting to see Len pem data now published by @AlbigesL & intriguing triplet data from @BradMcG04 (@montypal)
10 months ago
10ms
💫🎙️ Podcast Highlights: The Emergence of Triplet Therapies in ccRCC in the Frontline Setting 🎙️💫 🔆 Recommended In a recent podcast, @PBarataMD and Dr Naomi Hass discussed the following ✳key points: 1️⃣ Results and Trials: 🟡Multiple clinical trials are investigating… https://t.co/p5FG054qa4 (@nataliagandur)
10 months ago
Clinical
10ms
🎙️ Guest host @PBarataMD of @UHhospitals and Dr. Naomi Haas of @PennMedicine discuss triplet therapies for #ccRCC in the frontline setting and response-adaptive treatment strategies on the #ASCODailyNews Podcast: https://t.co/JKb7XzUuP3 #kcsm (@ASCO)
10 months ago
Clinical
10ms
💫🎙️ Destacados del Podcast: La Emergencia de Terapias con Tripletes en ccRCC en el Contexto de Primera Línea 🎙️💫 🔆 Recomendado En un podcast reciente, @PBarataMD y la Dra. Naomi Haas discutieron los siguientes ✳puntos clave: 1️⃣ Resultados y Ensayos: 🟡 Múltiples ensayos… https://t.co/mspInGwwHG (@nataliagandur)
10 months ago
10ms
💫🎙️ Destacados del Podcast: La Emergencia de Terapias con Tripletes en ccRCC en el Contexto de Primera Línea 🎙️💫 🔆 Recomendado En un podcast reciente, @PBarataMD y la Dra. Naomi Haas discutieron los siguientes ✳puntos clave: 1️⃣ Resultados y Ensayos: 🟡 Múltiples ensayos… https://t.co/bOYjntJoD6 (@nataliagandur)
10 months ago
10ms
💫🎙️ Podcast Highlights: The Emergence of Triplet Therapies in ccRCC in the Frontline Setting 🎙️💫 🔆 Recommended In a recent podcast, @PBarataMD and Dr Naomi Hass discussed the following ✳key points: 1️⃣ Results and Trials: 🟡Multiple clinical trials are investigating… https://t.co/zEc7aWZSh3 (@nataliagandur)
10 months ago
Clinical
10ms
Very interesting and accessible talk by @KimrynRathmell @VUMChealth re: RCC metabolism at #KCRS23 @kidneycan . Asks a great fundamental Q: Why are some ccRCC tumors negative on FDG-PET? Fascinating data on tumor-associated macrophage uptake of glucose in microenvironment (@EvanHallMD)
10 months ago
FDG PET
10ms
S3: Trials In Progress ⭐️ STARLITE 1 Phase 1/2 Study of Combo 177Lu Girentuximab + Cabo + Nivo in Treatment Naive ccRCC @EJonasch @MDAndersonNews @DrEHasanov @kidneycan #KCRS23 (@MikeSerzanMD)
10 months ago
P1/2 data
|
Opdivo (nivolumab) • Rencarex (girentuximab)
10ms
@EJonasch on the STARLITE 1: a phase 1/2 study of combination 177Lu Girentuximab plus Cabo and Nivo in ccRCC @kidneycan #KCRS23 (@MosheOrnsteinMD)
10 months ago
P1/2 data
|
Opdivo (nivolumab) • Rencarex (girentuximab)
10ms
Dr. Gupta @bmsnews presents on biomarkers for IO response in ccRCC at #KCRS23 biomarker symposium @kidneycan. Interesting summary of data of ECM factors, which appear prognostic in CM214 analyses but not clearly predictive of OS. (@EvanHallMD)
10 months ago
10ms
nccRCC à l'honneur today! @DrChoueiri presents SAMETA a ph3 study in pts w/ papillary RC Right before tackling another stellar presentation! @OncoAlert #KCRS23 (@ReneeSaliby)
10 months ago
Clinical
10ms
@VincentWenxinXu from @DanaFarber presenting at #KCRS23 @kidneycan on KIM-1 in ccRCC. Well-presented and a nice summary of past, ongoing, and future directions. (@EvanHallMD)
10 months ago
KIM1 (Kidney injury molecule 1)
10ms
Excellent work by @ReneeSaliby from study of AtezoBev in nccRCC investigating circulating biomarkers. @BraunMDPhD @DrChoueiri #KCRS @kidneycan (@DrRanaMcKay)
10 months ago
10ms
Amazing data! Along with recent cabo/nivo data in non-ccRCC, these data further support IO/TKI as a SOC Tx option for many pts with nccRCC. Gr8 to have multiple prospective IO/TKI datasets. Congrats @AlbigesL and team and kudos to pharma for funding trials in rare disease subsets (@MosheOrnsteinMD)
10 months ago
Clinical
|
Opdivo (nivolumab) • Cabometyx (cabozantinib tablet)
10ms
Congrat’s Laurence for this important trial for our nccRCC patients. (@GabrielMalouf)
10 months ago
Clinical
10ms
Congratulations @AlbigesL and team!! 👏🏽👏🏽👏🏽 great to see more therapeutic options for non-ccRCC! #kcsm (@_ShankarSiva)
10 months ago
10ms
Well done Pedro and Monty very important to get as much clinical data as possible in rare / less common diseases like nccRCC. Great work 👏🏾 (@AzadOncology)
10 months ago
Clinical data
11ms
@Uromigos Awesome episode discussing IO/IO vs TKI/IO outcomes in ccRCC. Strongly recommend listening to this plus @BraunMDPhD ‘s incredible discussion following the oral abstracts at ASCO to get a key look at challenges we face as a field! https://t.co/kK1MoQZXId (@rmelias2)
11 months ago
11ms
Amazing work by 🌟 superstar @ReneeSaliby investigating molecular determinants of response to Atezo+Bev among patients with #nccRCC , out now in @CIR_AACR Congrats to the whole team!!! @BraunMDPhD @DrRanaMcKay @DrChoueiri @ZiadBakouny @TalalZarif1 (@Chrislabaki1)
11 months ago
Clinical
|
Avastin (bevacizumab)
11ms
Belzutifan plus lenvatinib generated responses and displayed a manageable safety profile in patients with advanced ccRCC whose disease progressed following treatment with a PD-1/L1 inhibitor and a VEGF TKI. @AlbigesL #oncology #kcsm #ASCO23 https://t.co/k6NoeaF63W (@OncLive)
11 months ago
Clinical • Metastases
|
Lenvima (lenvatinib) • Welireg (belzutifan)
11ms
@DrTHut 4-yr F/U of PhIII CLEAR len+pembro in #1L adv ccRCC adjusted OS benefit over sunitinib maintained w/71.3% ORR (CR 18.3%) vs 36.7% (CR 5%), depth of response was prognostic of OS. DOR median 26.7 w/combo vs 14.7 mos w/sunitinib #ASCO23 @OncoAlert (@jgong15)
11 months ago
Keytruda (pembrolizumab) • Sutent (sunitinib) • Lenvima (lenvatinib)
11ms
5-Year KEYNOTE-426 Update: Pembro + Axi vs Sun 1L Rx for adv ccRCC @brian_rini @urotoday #ASCO23 Pembro + Axi vs Sun: ♦️ PFS: HR 0.69, 95% CI 0.59-0.81 ♦️ OS: HR 0.84, 95% CI 0.71-0.99 ♦️ ORR: 60.6% vs 39.6% ♦️ mDOR: 23.6 vs 15.3 mo ♦️ IMDC int/poor risk - OS: HR 0.76, 95% CI… https://t.co/sAedahrcEc (@zklaassen_md)
11 months ago
Keytruda (pembrolizumab)
11ms
@DrChoueiri rand PhIII CONTACT-03 adv #ccRCC/nccRCC post-ICI (ICI immediately preceding) cabo/atezo didn’t improve PFS or OS over cabo (ORR 41% both), subgroups didn’t identify pts who benefit from ICI-rechallenge. Although neg study, imp findings in era of #IO #ASCO23 @OncoAlert (@jgong15)
11 months ago
Clinical
11ms
Tip: Ph 1b/2 study of 177Lu girentuximab + Cabo + Nivo in Rx-naïve pts w/ adv ccRCC @DrEHasanov @urotoday #ASCO23 🔹 Target: n=100 🔹 177Lu-girentuximab 1480 MBq/m2 every 12 wks for up to 3 Rx cycles 🔹 After 1st cycle, Nivo + Cabo added 🔹 Prim EP: Safety, CR by RECIST 1.1… https://t.co/rrwy8159hl (@zklaassen_md)
11 months ago
Clinical
|
Opdivo (nivolumab) • Rencarex (girentuximab)
11ms
Triple Therapy in #nccRCC? ➡️Final results of #CaNI trial: triple therapy w/ cabo/nivo/ipi in pts with nccRCC -Safety concern: 74% G3-4 AE (10% cardiac) -CR: 0% -ORR all/1L: 18/21% -mPFS 8.9m -mOS NR, 12m OS 79% @BradMcG04 @OncoAlert @urotoday #ASCO23 ?doublet>triplet (@jordanciuro)
11 months ago
Clinical
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet)
11ms
@schmidingerRCC: 1) PhII KN-B61 #1L len + pembro adv #nccRCC 49% ORR (6% CR), med DOR NR & PFS 17.9 mos, 2) #IMDC study #1L IO-based tx’s > VEGF-TKIs in sarc/rhabdoid nccRCC, 3) PhII #1L cabo/nivo/ipi 18% ORR & high G3/4 AEs doublet likely > triplet in nccRCC #ASCO23 @OncoAlert (@jgong15)
11 months ago
VEGFA (Vascular endothelial growth factor A)
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet)
11ms
Belzutifan/Lenvatinib Elicits Responses in Advanced ccRCC After Progression on Checkpoint Inhibitor and VEGF TKI @AlbigesL @ASCO #ASCO23 #kcsm https://t.co/SskKpMmBIK (@OncLive)
11 months ago
Checkpoint inhibition • Metastases
|
Lenvima (lenvatinib) • Welireg (belzutifan)
11ms
Manuela Schmidinger, MD; eloquently discussed 3 non-clear cell carcinoma abstract to make it clear! ⭕️ Why is the Treatment of non-ccRCC still a challenge in 2023? @ASCO #ASCO23 @OncoAlert @IMDConline @DanaFarber_GU @DrChoueiri @DrDanielHeng @Uromigos (@DrYukselUrun)
11 months ago
11ms
A true honor to share the stage with #GU Onc legends @apolo_andrea @BradMcG04 @ChungHanLee3 and have our work discussed by the great @schmidingerRCC A dedication to my amazing mentors and colleagues, and patients with #nccRCC for whom we aim to achieve better outcomes @ASCO (@Chrislabaki1)
11 months ago
Clinical
11ms
The tolerability of single agent PD1 blockade is also a plus in comparison to prior generations of cytotoxics. So these are relatively ideal drugs for neoadjuvant trials. Hopefully we can have some trials in ccRCC! (@BReinfeld)
11 months ago
Clinical
11ms
Phase 2 Study of Batiraxcept (AVB-S6-500, an AXL inhibitor) as Monotherapy, in Combination With Cabozantinib (Cabo), and in Combination With Cabo and Nivolumab (Nivo) in Patients With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) @xingao04 #MGCCatASCO23 https://t.co/I4j2RKV3WG (@MGHCancerCenter)
11 months ago
Clinical • Combination therapy • Metastases
|
Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • batiraxcept (AVB-500)
11ms
Don't miss! 📢 Poster presentation by @AlbigesL @GustaveRoussy - Belzutifan + Lenvatinib for advanced #ccRCC after PD-1/L1 and VEGF inhibitor progression. Preliminary results from #KEYMAKERU03B. Written coverage to follow on UroToday > https://t.co/JohbdZbjLm #ASO23 @ASCO (@urotoday)
11 months ago
Metastases
|
Lenvima (lenvatinib) • Welireg (belzutifan)
11ms
Inner nerd ❤️s these top 5 #RCC translational studies @ASCO #ASCO23 🔸 nivo-resistance biomarkers - @BraunMDPhD 🔸 AI to select in #OPTICRCC - @brian_rini 🔸 nccRCC immune landscape - @ReneeSaliby 🔸 molec diffs by ancestry - @rmelias2 🔸Biopsies in #PROSPER - @NaomiHaas5 (@TiansterZhang)
11 months ago
Biopsy
|
Opdivo (nivolumab)
11ms
Here are my top 5 #kidneycancer trials @ASCO #ASCO23 🔸#CONTACT03 cabo-atezo -- @DrChoueiri 🔸 #CAN-I (cabo/ipi/nivo) in nccRCC -- @BradMcG04 🔸 #KeynoteB61 pembro-len in nccRCC -- @ChungHanLee3 🔸 #BatiraxceptCabo -- @katy_beckermann 🔸 #CLEAR OS -- @motzermd @OncoAlert (@TiansterZhang)
11 months ago
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • Lenvima (lenvatinib) • Cabometyx (cabozantinib tablet)
11ms
Left: ccRCC grade 2 pT1b negative margins. Right: ccRCC grade 3 pT2a negative margins. Waiting for the genetic evaluation Thank yo very much for the advice (@davidlorente2)
11 months ago
11ms
RR continue to climb in @ChungHanLee3 @motzermd @MSKCancerCenter trial of cabo/nivo in nccRCC. Need to establish role of TKI/IO in nccRCC - best way to do this is to support trials like @SWOG 2200 & #STELLAR304. @uromigos @brian_rini @tompowles1 @ASCO #ASCO23 (@montypal)
11 months ago
Opdivo (nivolumab) • Cabometyx (cabozantinib tablet)
11ms
Proud of @ShuchiGulati @UCD_Cancer for putting together a detailed analysis of rare histologies embedded in @SWOG #EVEREST. Impt to bear in mind evolving perspective of mTORi in nccRCC dating back to trials like #ESPN & #ASPEN. @PrimoLaraMD @KidneyCancerDoc #ASCO23 (@montypal)
11 months ago
11ms
🌟 Significant Survival Benefit Seen With #IO-Based Regimens for #Sarcomatoid and/or #Rhabdoid Metastatic #Non–Clear Cell #RCC 🌟 @Chrislabaki1 @ASCO @ASCOPres #ASCO23 @OncoAlert @OncoReporte https://t.co/MYgig6rLOk (@nataliagandur)
11 months ago
Metastases
11ms
Patients receiving cytoreductive nephrectomy regardless of sequence with IO did better than IO alone in this national registry-based adjusted analysis for mccRCC. #ASCO23 @IMG_Oncologists @ASCO https://t.co/qwE2FTJbwp (@MarounBouZerdan)
11 months ago
Clinical
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login